Recommended Topic Related To:
PrismaSol Solution
FDA Approves Procysbi for Rare Genetic Condition »
"The U.S. Food and Drug Administration today approved Procysbi (cysteamine bitartrate) for the management of nephropathic cystinosis in children and adults. Procysbi was granted orphan product designation because it is intended to treat a rare dis"...
Read the FDA Approves Procysbi for Rare Genetic Condition article »
PrismaSol Solution
CONTRAINDICATIONS
None.
Last reviewed on RxList: 12/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Next: Drug Description
Additional PrismaSol Solution Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
